PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Specialty cancer diagnostics companies continue to operate in a dynamic healthcare environment influenced by advances in precision medicine, molecular testing and growing demand for personalized diagnostic solutions. Against this backdrop, Precipio, Inc. PRPO and Biodesix, Inc. BDSX are two companies focused on improving cancer diagnostics through specialized testing and related diagnostic solutions. PRPO combines clinical laboratory services with proprietary diagnostic product development, with its pathology services focused primarily on hematologic cancers. BDSX, meanwhile, provides blood-based diagnostic testing focused on lung disease, including tests that assess the risk of cancer in lung nodules and guide treatment following a lung cancer diagnosis.

While both companies operate in cancer diagnostics, they differ in their business focus, service offerings and market presence. Precipio combines specialized pathology services with proprietary diagnostic products, while Biodesix primarily offers blood-based lung diagnostic testing alongside development services for biopharmaceutical and life sciences companies. These differences result in distinct business models, competitive positioning and financial profiles, ultimately shaping each company's investment appeal. This raises an important question: which stock is better positioned for investors today? Let's take a closer look.

Stock Performance & Valuation: PRPO vs. BDSX

PRPO (up 26.4%) has underperformed BDSX (up 64.5%) over the past three months. In the past year, Precipio has gained 112% compared with Biodesix’s gain of 150.9%.

Image Source: Zacks Investment Research

Meanwhile, PRPO is trading at a trailing 12-month enterprise value-to-sales (EV/S) ratio of 1.90X, above its median of 1.23X over the past five years. BDSX’s trailing 12-month EV/S multiple sits at 2.89X, above its last five-year median of 2.24X. PRPO and BDSX both appear to be cheap when compared with the Zacks Medical sector average of 2.92X.

Image Source: Zacks Investment Research

Factors Driving Precipio Stock

Precipio is strengthening the commercial foundation of its products business, which could become an increasingly important growth contributor. During the second quarter of 2026, its commercial team added roughly 10 distributor representatives, identified more than 25 qualified customers and continued building its sales pipeline. Existing relationships with Thermo Fisher, McKesson, Medline and Cardinal Health provide extensive coverage of the targeted market. Management expects pipeline opportunities to increasingly convert into active accounts during the second half of 2026.

Precipio’s pathology infrastructure provides an important advantage in developing diagnostic products. Its laboratories give the company access to patient specimens, clinical workflows and direct clinician feedback, allowing assays to be developed, evaluated and refined in a real-world environment. By leveraging existing revenue-generating infrastructure, PRPO can potentially reduce development costs and timelines while keeping innovation closely aligned with clinical needs.

Precipio’s financial profile is showing signs of greater sustainability as operations scale. The company generated operating cash flow in the second quarter of 2026 while simultaneously investing in business growth, and its cash balance increased organically without a financing event. This progress, alongside positive adjusted EBITDA, indicates improving operating leverage and could reduce dependence on external capital to support expansion.

Factors Aiding Biodesix Stock

Biodesix is seeing broader adoption of its Nodify Lung tests across pulmonology and primary care, supported by both new ordering physicians and increased utilization within existing accounts. Expanding clinical evidence is further reinforcing this momentum. Recent validation of Nodify CDT in smaller lung nodules has encouraged physicians to use the test in this population and subsequently broaden utilization across the lung-nodule continuum.

Improving payer coverage is enhancing the commercial profile of Biodesix’s diagnostic portfolio. Average revenue per test improved year over year, primarily reflecting additional payer coverage and better revenue-cycle management rather than one-time benefits. Continued reimbursement gains could make broader adoption more economically meaningful while supporting BDSX’s high gross-margin profile and progress toward profitability.

Biodesix is leveraging its existing infrastructure and multi-omic capabilities to advance new diagnostics without requiring a separate development platform. Its Development Services relationships with biopharma, life-sciences and research organizations also provide access to additional projects and clinical insights. Together, internal development and external collaborations could expand future revenue opportunities beyond the currently marketed portfolio.

Choose PRPO Over BDSX Now

Both Precipio and Biodesix have identifiable growth drivers in cancer diagnostics, but their investment cases differ. PRPO is expanding the commercialization of its proprietary diagnostic products while using its pathology infrastructure to support product development and validation. Its improving self-funding capacity adds another positive element, as greater internal cash generation can support expansion while reducing dependence on external financing.

BDSX, meanwhile, is benefiting from broader adoption of its Nodify Lung tests across pulmonology and primary care. Expanding clinical evidence and improving reimbursement are supporting the commercial profile of its diagnostic portfolio. The company's Development Services business and diagnostic pipeline provide additional growth avenues through relationships with biopharma, life-sciences and research organizations.

From a valuation perspective, Precipio currently appears more attractively priced than Biodesix. Although both stocks are valued above their respective historical norms, PRPO trades at a lower valuation than BDSX and at a discount to the broader sector. This indicates that investors are paying less for PRPO's sales despite the company's ongoing commercialization progress. BDSX's stronger recent share-price appreciation and higher valuation, meanwhile, suggest that investors are assigning a greater premium to its growth prospects.

Considering PRPO's comparatively attractive valuation, expanding product commercialization, integrated pathology-product model and improving financial sustainability, Precipio appears to be the better buy now. Biodesix retains compelling growth prospects, but PRPO's combination of fundamental progress and a less demanding valuation provides a more favorable investment proposition at present.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research